3 news items
Ultragenyx, Mereo Report 14-Month Results From Phase 2 Portion Of Phase 2/3 Orbit Study; Treatment With Setrusumab Resulted In Sustained 67% Reduction In Annualized Fracture Rate In Osteogenesis Imperfecta Patients
MREO
RARE
11 Jun 24
with OI with at least 14 months of follow-up. Treatment with setrusumab also resulted in ongoing and meaningful improvements in lumbar spine bone mineral
Ultragenyx and Mereo BioPharma Announce New Phase 2 Data from Phase 2/3 Orbit Study Demonstrating Sustained Reductions in Fracture Rates Following Treatment with Setrusumab (UX143) in Patients with Osteogenesis Imperfecta (OI)
MREO
RARE
11 Jun 24
fracture rate of 0.00 (p=0.0014) Treatment resulted in continued, substantial improvements in bone mineral density (BMD
Mereo BioPharma Reports Full Year 2023 Financial Results and Provides Corporate Update
MREO
27 Mar 24
with OI who had been treated for at least 6 months. This reduction was associated with improvements in bone mineral density (BMD). Setrusumab was well
- Prev
- 1
- Next